ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3

  • Ebbing E
  • Medema J
  • Damhofer H
  • et al.
N/ACitations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Receptor tyrosine kinases of the HER-family are involved in the development and progression of multiple epithelial tumors, and have consequently become widely used targets for new anti-cancer therapies. Trastuzumab, an antibody against HER2, has shown potent growth inhibitory effects on HER2 overexpressing tumors, including gastro-esophageal cancer, however, resistance to this therapy is inevitable. Unfortunately, a paucity of data on the cellular mechanisms of resistance to targeted therapeutic agents exists in esophageal adenocarcinoma. Using primary established HER2-overexpressing cultures and patient-derived xenograft models, we now reveal a novel resistance mechanism to trastuzumab in esophageal cancer: In response to trastuzumab, both HER3 and the metalloprotease ADAM10 are simultaneously upregulated. The proteolytic activity of the latter then releases the HER3 ligand heregulin from the cell surface to activate HER3 and confer resistance to trastuzumab by inducing compensatory growth factor receptor signaling. Blocking either HER3 or ADAM10 effectively reverts the acquired resistance to trastuzumab. Our data thus provide strategies to inhibit this signaling and circumvent resistance to trastuzumab.

Cite

CITATION STYLE

APA

Ebbing, E. A., Medema, J. P., Damhofer, H., Meijer, S. L., Krishnadath, K. K., Henegouwen, M. I. van B., … van Laarhoven, H. W. M. (2016). ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. Oncotarget, 7(9). https://doi.org/10.18632/oncotarget.7200

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free